These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 12243982)

  • 1. Troxacitabine activity in extramedullary myeloid leukemia.
    Alvarado Y; Kantarjian HM; Cortes JE; Apostolidou E; Bivins C; Giles FJ
    Hematology; 2002 Jun; 7(3):179-85. PubMed ID: 12243982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
    J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
    Giles FJ; Cortes JE; Baker SD; Thomas DA; O'Brien S; Smith TL; Beran M; Bivins C; Jolivet J; Kantarjian HM
    J Clin Oncol; 2001 Feb; 19(3):762-71. PubMed ID: 11157029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
    Giles FJ; Garcia-Manero G; Cortes JE; Baker SD; Miller CB; O'Brien SM; Thomas DA; Andreeff M; Bivins C; Jolivet J; Kantarjian HM
    J Clin Oncol; 2002 Feb; 20(3):656-64. PubMed ID: 11821445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
    Giles FJ; Kantarjian HM; Cortes JE; Garcia-Manero G; Verstovsek S; Faderl S; Thomas DA; Ferrajoli A; O'Brien S; Wathen JK; Xiao LC; Berry DA; Estey EH
    J Clin Oncol; 2003 May; 21(9):1722-7. PubMed ID: 12721247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
    Roboz GJ; Giles FJ; Ritchie EK; Allen-Bard S; Curcio TJ; Wilkes MA; Park SL; Kantarjian HM; Faderl S; Ravandi F; Kelner MJ; Feldman EJ
    J Clin Oncol; 2007 Jan; 25(1):10-5. PubMed ID: 17146106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
    Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Troxacitabine-based therapy of refractory leukemia.
    Giles FJ
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):261-6. PubMed ID: 12113049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    de Bono JS; Stephenson J; Baker SD; Hidalgo M; Patnaik A; Hammond LA; Weiss G; Goetz A; Siu L; Simmons C; Jolivet J; Rowinsky EK
    J Clin Oncol; 2002 Jan; 20(1):96-109. PubMed ID: 11773159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
    Lin CC; Beeram M; Rowinsky EK; Takimoto CH; Ng CM; Geyer CE; Denis LJ; De Bono JS; Hao D; Tolcher AW; Rha SY; Jolivet J; Patnaik A
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):167-75. PubMed ID: 19449006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity.
    Gourdeau H; Bibeau L; Ouellet F; Custeau D; Bernier L; Bowlin T
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):236-40. PubMed ID: 11320667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
    Vose JM; Panwalkar A; Belanger R; Coiffier B; Baccarani M; Gregory SA; Facon T; Fanin R; Caballero D; Ben-Yehuda D; Giles F
    Leuk Lymphoma; 2007 Jan; 48(1):39-45. PubMed ID: 17325846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Troxacitabine in leukemia.
    Swords R; Apostolidou E; Giles F
    Hematology; 2006 Oct; 11(5):321-9. PubMed ID: 17607581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Troxacitabine in acute leukemia.
    Swords R; Giles F
    Hematology; 2007 Jun; 12(3):219-27. PubMed ID: 17558697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
    Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
    Lee CK; Rowinsky EK; Li J; Giles F; Moore MJ; Hidalgo M; Capparelli E; Jolivet J; Baker SD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2158-65. PubMed ID: 16609029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia.
    Quintás-Cardama A; Cortes J
    Expert Opin Investig Drugs; 2007 Apr; 16(4):547-57. PubMed ID: 17371201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.